Influence of anti‐rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipients

This publication has 11 references indexed in Scilit:

• Preemptive Ganciclovir Therapy in Cytomegalovirus-Seropositive Renal Transplants Recipients
  Archives of Surgery, 1995
• Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant Recipients
  Annals of Internal Medicine, 1995
• A RANDOMIZED PROSPECTIVE TRIAL OF PROPHYLACTIC IMMUNOSUPPRESSION WITH ATG-FRESENIUS VERSUS OKT3 AFTER RENAL TRANSPLANTATION
  Transplantation, 1995
• Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants
  The American Journal of Medicine, 1993
• DILTIAZEM IN RENAL ALLOGRAFT RECIPIENTS RECEIVING CYCLOSPORINE
  Transplantation, 1993
• SEQUENTIAL THERAPY—A PROSPECTIVE RANDOMIZED TRIAL OF MALG VERSUS OKT3 FOR PROPHYLACTIC IMMUNOSUPPRESSION IN CADAVER RENAL ALLOGRAFT RECIPIENTS
  Transplantation, 1992
• A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts
  New England Journal of Medicine, 1989
• INCREASED INFECTIONS ASSOCIATED WITH THE USE OF OKT3 FOR TREATMENT OF STEROID-RESISTANT REJECTION IN RENAL TRANSPLANTATION1 Pressented at the 6th Annual Meeting of the American Society of Transplant Physicians, May 1987, Chicago, IL
  Transplantation, 1988
• Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant Recipients
  New England Journal of Medicine, 1987
• Infection in the renal transplant recipient
  The American Journal of Medicine, 1981